Avalyn Pharma Inc. (AVLN) Key Metrics
AVLN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.05B
- Enterprise value
- $982.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
AVLN key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAVLN returns How much profit the business earns on the capital it uses.
AVLN per-share figures Results divided by the shares outstanding at year-end.
AVLN financial health Debt, liquidity and how easily interest is covered.
AVLN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AVLN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AVLN key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$2.04 | −$1.19 |
| Operating cash flow per share | −$1.95 | −$1.16 |
| Free cash flow per share | −$1.96 | −$1.16 |
| Cash per share | $3.31 | $0.57 |
| Book value per share | −$5.71 | −$4.17 |
| Tangible book value per share | −$5.71 | −$4.17 |
| Capex per share | $0.01 | $0.00 |
| Debt per share | $0.04 | — |
| Shares outstanding | 41.8M | 41.8M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −62.3% | −39.9% |
| Return on tangible assets | −57.2% | −39.9% |
| Financial health | ||
| Total debt | $1.7M | — |
| Cash & short-term investments | $138.4M | $24.0M |
| Net debt | −$136.7M | −$24.0M |
| Debt / assets | 0.01 | — |
| Current ratio | 10.19 | 13.08 |
| Quick ratio | 10.19 | 13.08 |
| Working capital | $129.5M | $105.6M |
| Invested capital | −$375.3M | −$198.5M |
| Tangible asset value | −$238.7M | −$174.5M |
| Net current asset value | −$244.0M | −$184.7M |
| Graham net-net per share | −$5.95 | −$6.58 |
| Capital allocation | ||
| Capex / depreciation | 8.19 | 3.28 |
| Efficiency | ||
| Receivables turnover | 0.00 | — |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | $537,000 | — |
| Average payables | $3.0M | $2.3M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from AVLN's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AVLN valuation and financial ratios
It ended the year with $1.7 million of debt and $138.4 million in cash and short-term investments, a net cash position of $136.7 million.
See the AVLN income statement, the AVLN chart for price history, or the AVLN stock overview for the latest quote and news.
AVLN key metrics FAQ
How much debt does Avalyn Pharma have?
Avalyn Pharma had total debt of $1.7 million at the end of fiscal 2025 and more cash than debt.
What is Avalyn Pharma's current ratio?
Avalyn Pharma's current ratio was 10.19 at the end of fiscal 2025: current assets were 10.19 times current liabilities.